MarioNawfal

The Wall Street Journal

More Big Drugmakers Reach Pricing Deals With White House Kgn1Auhvq7Bedo975Zvn

The New York Times

Trump Drug Pricing Deals.Html

FOX News

Trump secures agreements with major drugmakers to lower Medicaid prescription costs for Americans

Trump White House

Fact Sheet: President Donald J. Trump Announces Largest Developments to Date in Bringing Most-Favored-Nation Pricing to American Patients

CNBC

Nine of the largest pharma companies ink deals with Trump to lower drug prices

Newsmax

1238960

US drug prices: Trump announces most favored nation deals with nine drug companies

The Washington Post

Trump Drug Price Cuts

Trump Speech Tariffs Economy Checks

Donald Trump

Torsten Sløk

Kevin Ryan

Scott Bessent

Spencer Hakimian

Lance Jungmeyer

Dino Bianco

Christian Science Monitor

Ryan Petersen

Rob Handfield

John Harmon

Jason Miller (MSU)

Marc Morial

Phil Lempert

Craig Fuller

Karyn Rispoli

Sean Stein

The Independent

"I wouldn't think that we would have supply chain shocks."

"There's unlikely to be a food shortage."

"We don't have shortages right now, nor should we expect any in these areas [agricultural products]."

"That [the decreasing flow of container ships from China to the US] will lead to empty shelves in stores."

"Empty shelves coming to you soon."

"The consequence [of Trump's trade policies] will be empty shelves in US stores in a few weeks and Covid-like shortages."

Torsten Slok

"Like back during Covid where we had shortages of toilet paper, we are going to start seeing that in more and more goods."

"Well, maybe the children will have two dolls instead of 30 dolls."

Will Grocery Stores in the US Experience Empty Shelves/Item Shortage Under Trump 2.0?

President Trump announced on Friday that nine pharmaceutical companies agreed to reduce certain U.S. drug prices to levels comparable with prices in other wealthy countries. The companies include Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis and Sanofi.

President Trump announced on Friday that nine pharmaceutical companies agreed to reduce certain U.S. drug prices to levels comparable with prices in other wealthy countries. The companies include Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis and Sanofi.

The agreements bring the total number of drugmakers participating in the administration's most favored nation pricing initiative to 14 out of 17 companies initially targeted. Three companies have yet to announce deals: AbbVie, Johnson & Johnson and Regeneron.

The agreements bring the total number of drugmakers participating in the administration's most favored nation pricing initiative to 14 out of 17 companies initially targeted. Three companies have yet to announce deals: AbbVie, Johnson & Johnson and Regeneron.

Under the arrangements, manufacturers will offer reduced prices to state Medicaid programs and sell medications through direct to patient services including the planned TrumpRx website. In exchange, companies receive three year exemptions from potential pharmaceutical tariffs.

Under the arrangements, manufacturers will offer reduced prices to state Medicaid programs and sell medications through direct to patient services including the planned TrumpRx website. In exchange, companies receive three year exemptions from potential pharmaceutical tariffs.

The nine companies collectively committed to invest at least $150 billion in U.S. manufacturing and research and development. Several companies also agreed to donate active pharmaceutical ingredients to a national emergency stockpile for use during pandemics or disasters.

The nine companies collectively committed to invest at least $150 billion in U.S. manufacturing and research and development. Several companies also agreed to donate active pharmaceutical ingredients to a national emergency stockpile for use during pandemics or disasters.

Specific price reductions include Merck offering diabetes drugs Januvia and Janumet at 70% off list price and Amgen selling migraine drug Aimovig for $299 monthly, nearly 60% off list price. Bristol Myers Squibb will provide blood thinner Eliquis free to Medicaid patients.

Specific price reductions include Merck offering diabetes drugs Januvia and Janumet at 70% off list price and Amgen selling migraine drug Aimovig for $299 monthly, nearly 60% off list price. Bristol Myers Squibb will provide blood thinner Eliquis free to Medicaid patients.

Experts note the deals may provide limited overall savings to the U.S. health system, as Medicaid represents only about 10% of drug spending and already receives substantial discounts. The agreements do not address high costs for most drugs covered under private insurance or Medicare.

Experts note the deals may provide limited overall savings to the U.S. health system, as Medicaid represents only about 10% of drug spending and already receives substantial discounts. The agreements do not address high costs for most drugs covered under private insurance or Medicare.

9 Pharma Giants Agree to Cut U.S. Drug Prices

9 Pharma Giants Agree to Cut U.S. Drug Prices

The Controversies

Bessent

Fuller

Handfield

Ryan

Hakimian

Stein

Trump

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters

9 Pharma Giants Agree to Cut U.S. Drug Prices

9 Pharma Giants Agree to Cut U.S. Drug Prices

The Controversies

Bessent

Fuller

Handfield

Ryan

Hakimian

Stein

Trump

Sign Up for Our Free NewslettersSign Up for Our Free Newsletters

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters